This startup, born out of AION Labs’ startup challenge, aims to enhance the development of biological therapeutics by using the latest AI technologies.
The company says CombinAble.AI represents a bold departure from traditional antibody optimization methods, which often involve laborious trial-and-error processes.
By embracing advanced machine learning models and computational simulations, AION says the platform promises to accelerate the discovery of more effective therapeutic antibodies, potentially revolutionizing the drug development pipeline.
Advanced machine learning learning models
Daria Kokh, co-founder and CEO of CombinAble, explained the company’s approach, she said: “Our emphasis is on combining various advanced machine learning models, including large protein language models, molecular dynamics simulations, and multi-objective optimization algorithms, integrating them into a single unified solution for targeted antibody discovery.”
The company says the traditional pathway to antibody optimization is notorious for its time-consuming nature and high costs, with success far from guaranteed. CombinAble’s inventive methodology, it says, seeks to circumvent these challenges by enabling a model to “learn” from data and physics-based principles to identify optimal solutions in a single iteration.
Antibody optimization is a critical stage in the drug development process, involving the transformation of preliminary antibody hits into viable clinical candidates. By automating the selection of mutations that enhance multiple biophysical characteristics of antibody candidates, CombinAble.AI aims to speed up this process, potentially shortening development timelines and reducing costs.
AI poised to play a central role
Kokh highlighted the invaluable support provided by AION Labs in shaping CombinAble’s trajectory, she added: “As we progress, the knowledge and insights provided by its pharmaceutical partners will be invaluable for the development and commercialization of our solution.”
CombinAble.AI represents the latest addition to AION Labs’ portfolio of seminal startups, supported by global pharmaceutical and technology leaders. With its interdisciplinary team led by experts in biomolecular modeling, simulations, and data science, the company says CombinAble.AI is poised to drive innovation in the field of targeted antibody design.
The launch of CombinAble.AI, AION says, signals a paradigm shift in targeted antibody design, with AI poised to play a central role in optimizing and accelerating the discovery process.
Dedicated to transforming drug discovery
Mati Gill, CEO of AION Labs, expressed excitement about the potential impact of CombinAble, he said: “We are delighted to welcome CombinAble into the AION Labs ecosystem and look forward to working closely with the team to develop solutions that enable the design of highly effective biological therapeutics.”
AION Labs is dedicated to transforming drug discovery and development through the adoption of AI technologies. Supported by leading pharmaceutical and technology partners, the company says it fosters innovation and collaboration to address the most pressing challenges in healthcare.
